|
See related Dysport inj information |
|
|
|
Manufacturer |
Ipsen |
|
Distributor |
Zuellig |
|
Contents |
Clostridium botulinum type A toxin-haemagglutinin complex |
|
Indications |
Listed in Dosage. |
|
Dosage |
Arm spasticity 1,000 u IM distributed among 5 muscles. Paed cerebral palsy spasticity Childn >2 yr Initially 20 u/kg body wt IM as a divided dose between both calf muscles. Max: 1,000 u. May be repeated approx every 16 wk but not more frequently than every 12 wk. Spasmodic torticollis Adult & elderly Initially 500 u IM as a divided dose administered to 2 or 3 most active neck muscles, repeat approx every 12 wk. Max: 1,000 u. Blepharospasm & hemifacial spasm Adult & elderly Initially 120 u/eye SC. Repeated approx 12 wk or as required. |
|
Special Precautions |
Marked defective neuromuscular transmission. Underlying neurological disorders including swallowing difficulties. History of dysphagia & aspiration. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Generalised weakness, fatigue, flu-like syndrome, pain/bruising at inj site, dysphagia; muscle weakness; accidental injury/falls, diarrhoea, vomiting, urinary incontinence, abnormal gait, dysphonia, ptosis, diplopia, dry eyes, tearing, eyelid oedema.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs affecting neuromuscular transmission eg aminoglycosides.
View more drug interactions with Dysport |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Dysport injection |
|
|
|
Manufacturer: |
Ipsen |
|
Distributor: |
Zuellig |
|
Marketer: |
Invida
|
|
|
|
